Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Altimmune, Inc. | v466109_8k.htm |
| EX-99.1 - EXHIBIT 99.1 - Altimmune, Inc. | v466109_ex99-1.htm |
| EX-10.3 - EXHIBIT 10.3 - Altimmune, Inc. | v466109_ex10-3.htm |
| EX-10.2 - EXHIBIT 10.2 - Altimmune, Inc. | v466109_ex10-2.htm |
| EX-10.1 - EXHIBIT 10.1 - Altimmune, Inc. | v466109_ex10-1.htm |
| EX-3.3 - EXHIBIT 3.3 - Altimmune, Inc. | v466109_ex3-3.htm |
| EX-3.2 - EXHIBIT 3.2 - Altimmune, Inc. | v466109_ex3-2.htm |
| EX-3.1 - EXHIBIT 3.1 - Altimmune, Inc. | v466109_ex3-1.htm |
Exhibit 16.1
| Securities and Exchange Commission | May 5, 2017 |
| 100 F Street, N.E. | |
| Washington, DC 20549 |
Ladies and Gentleman:
We have read Item 4.01 of Form 8-K dated May 5, 2017, of Altimmune, Inc. and are in agreement with the statements contained in paragraphs 6-8 on page 3 therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young LLP